Author Archive for: panglobal

Entries by panglobal

StemInov secures €10.6 million to advance mesenchymal stem cell therapy for severe pneumonia

8 November 2025 in /by

French biopharmaceutical company StemInov has closed a €10.6 million financing round to support the industrialisation of its stem cell platform and prepare for Phase I/IIa clinical trials targeting severe pneumonia complications. The Nancy and Illkirch-Graffenstaden-based company, which specialises in mesenchymal stem cell (MSC) therapies for inflammatory and autoimmune diseases, expects to initiate patient recruitment in […]

Anti-laminin β4 – a new autoantibody marker in pemphigoid disease

8 November 2025 in , /by

Laminin β4 (lamβ4) has been identified as a novel target antigen in anti-p200 pemphigoid, a rare autoimmune disease manifesting with subepidermal blisters. Anti-lamβ4 antibodies bind to the region of the dermal–epidermal junction and demonstrate pathogenic effects. A recombinant-cell indirect immunofluorescence assay has been developed for specific detection of anti-lamβ4 antibodies.

Identification of putative breath biomarkers for detection of lymphoma

8 November 2025 in , /by

Volatile organic compounds (VOCs) are released from our bodies in our breath, sweat, blood and urine as a result of metabolic activity and so provide a window on our metabolic and physiological status. These VOCs change in response to disease, providing the potential for disease-specific VOCs in the breath to be used as non-invasive biomarkers […]

ACD/Labs expands Katalyst D2D software capabilities for pharmaceutical development

8 November 2025 in /by

ACD/Labs has released version 25.4 of Katalyst D2D, extending the industry-leading workflow digitalisation software beyond its original high throughput experimentation applications to support process scale-up and material characterisation in pharmaceutical development. The enhanced platform enables pharmaceutical project teams to accelerate the design-make-test-analyse cycle from discovery through to clinical trials.

Point-of-care test for detection of the FKBP12 biomarker at single-molecule level

7 November 2025 in , /by

FK506 (tacrolimus) binding protein 12 (FKBP12) is involved in fundamental cellular processes as well as immunosuppression, neurodegenerative diseases and cancer. Hence, the ability to quickly and easily determine its levels is desirable. CLI caught up with Dr Pitruzzella, Dr Caminati and Prof. Cennamo to find out more about the point-of-care test that they have developed […]

Latest issue of Clinical laboratory

March 2026

CLi Cover MRCH 2026
Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.